Dr. Ahmad shares what’s ahead, including the Facial & Rhinoplasty Symposium in Boca Raton, registration opening this month for The Aesthetic MEET 2027 in Miami Beach, and important updates to the way the Society connects and engages with members.
This is my last newsletter as President of The Aesthetic Foundation, and it has been a busy and productive year. Our core mission is to support research that is relevant to practicing plastic surgeons and improve the safety and effectiveness of the procedures that we offer to our patients.
It is just about two months from The Aesthetic MEET, and we have no lack of education, networking, and fun for you to take part in while you are in Boston. There are many opportunities to engage with and support The Aesthetic Foundation during The MEET, and I look forward to connecting and sharing all that has been accomplished with you.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely used for Type 2 diabetes and weight management but may adversely affect skin quality, resulting in dermal thinning, decreased elasticity, and accelerated aging—a phenomenon referred to as “GLP-1 Face.”
The recent Facial and Rhinoplasty Symposium was a tremendous success – and a great example of how The Society is evolving to meet the needs of our members and the demands of a fast-changing industry.